MRM Health Joins Forces with Oncode and Netherlands Cancer Institute

MRM Health has announced a strategic collaboration with the Oncode Institute and the Netherlands Cancer Institute (NKI) to advance microbiome-based therapies that enhance cancer immunotherapy. This partnership unites MRM Health’s CORAL® platform with the expertise of Prof. Emile Voest’s research group, aiming to develop live biotherapeutic products to enhance the efficacy of immune checkpoint inhibitors (ICIs).

ICIs, while revolutionary in cancer therapy, face limitations such as immune-related adverse events and resistance. Recent studies suggest the gut microbiome’s potential to overcome these drawbacks. The collaboration will leverage microbiome science to potentially improve immunotherapy responses. MRM Health, through its proprietary technology, aims to restore microbiome balance, thereby boosting ICI effectiveness and patient outcomes.